200 related articles for article (PubMed ID: 32272809)
1.
Kurz L; Miklyaeva A; Skowron MA; Overbeck N; Poschmann G; Becker T; Eul K; Kurz T; Schönberger S; Calaminus G; Stühler K; Dykhuizen E; Albers P; Nettersheim D
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32272809
[TBL] [Abstract][Full Text] [Related]
2. A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment.
Nettersheim D; Jostes S; Fabry M; Honecker F; Schumacher V; Kirfel J; Kristiansen G; Schorle H
Oncotarget; 2016 Nov; 7(46):74931-74946. PubMed ID: 27572311
[TBL] [Abstract][Full Text] [Related]
3. Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors.
Nettersheim D; Berger D; Jostes S; Skowron M; Schorle H
J Cell Mol Med; 2019 Jan; 23(1):670-679. PubMed ID: 30460772
[TBL] [Abstract][Full Text] [Related]
4. Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights.
Müller MR; Burmeister A; Skowron MA; Stephan A; Bremmer F; Wakileh GA; Petzsch P; Köhrer K; Albers P; Nettersheim D
Clin Epigenetics; 2022 Jan; 14(1):5. PubMed ID: 34996497
[TBL] [Abstract][Full Text] [Related]
5. CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms.
Skowron MA; Vermeulen M; Winkelhausen A; Becker TK; Bremmer F; Petzsch P; Schönberger S; Calaminus G; Köhrer K; Albers P; Nettersheim D
Br J Cancer; 2020 Aug; 123(3):378-391. PubMed ID: 32418994
[TBL] [Abstract][Full Text] [Related]
6. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
[TBL] [Abstract][Full Text] [Related]
7. Targeting ARID1A mutations in cancer.
Mullen J; Kato S; Sicklick JK; Kurzrock R
Cancer Treat Rev; 2021 Nov; 100():102287. PubMed ID: 34619527
[TBL] [Abstract][Full Text] [Related]
8. Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress.
Tomihara H; Carbone F; Perelli L; Huang JK; Soeung M; Rose JL; Robinson FS; Lissanu Deribe Y; Feng N; Takeda M; Inoue A; Poggetto ED; Deem AK; Maitra A; Msaouel P; Tannir NM; Draetta GF; Viale A; Heffernan TP; Bristow CA; Carugo A; Genovese G
Cancer Res; 2021 Jan; 81(2):332-343. PubMed ID: 33158812
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Role of Synthetic Lethality in
Hein KZ; Stephen B; Fu S
J Immunother Precis Oncol; 2024 Feb; 7(1):41-52. PubMed ID: 38327752
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors.
Yu ZC; Li T; Tully E; Huang P; Chen CN; Oberdoerffer P; Gaillard S; Shih IM; Wang TL
Cancer Res; 2023 Aug; 83(16):2750-2762. PubMed ID: 37306706
[TBL] [Abstract][Full Text] [Related]
11. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.
Mandal J; Mandal P; Wang TL; Shih IM
J Biomed Sci; 2022 Sep; 29(1):71. PubMed ID: 36123603
[TBL] [Abstract][Full Text] [Related]
12. Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.
Park Y; Chui MH; Suryo Rahmanto Y; Yu ZC; Shamanna RA; Bellani MA; Gaillard S; Ayhan A; Viswanathan A; Seidman MM; Franco S; Leung AKL; Bohr VA; Shih IM; Wang TL
Clin Cancer Res; 2019 Sep; 25(18):5584-5594. PubMed ID: 31196855
[TBL] [Abstract][Full Text] [Related]
13. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.
Shen J; Peng Y; Wei L; Zhang W; Yang L; Lan L; Kapoor P; Ju Z; Mo Q; Shih IeM; Uray IP; Wu X; Brown PH; Shen X; Mills GB; Peng G
Cancer Discov; 2015 Jul; 5(7):752-67. PubMed ID: 26069190
[TBL] [Abstract][Full Text] [Related]
14. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
[TBL] [Abstract][Full Text] [Related]
15. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
[TBL] [Abstract][Full Text] [Related]
16. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI).
Banerjee S; Stewart J; Porta N; Toms C; Leary A; Lheureux S; Khalique S; Tai J; Attygalle A; Vroobel K; Lord CJ; Natrajan R; Bliss J
Int J Gynecol Cancer; 2021 Nov; 31(11):1471-1475. PubMed ID: 34518240
[TBL] [Abstract][Full Text] [Related]
17. Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy.
Xu S; Sak A; Niedermaier B; Erol YB; Groneberg M; Mladenov E; Kang M; Iliakis G; Stuschke M
Front Oncol; 2022; 12():999626. PubMed ID: 36249060
[TBL] [Abstract][Full Text] [Related]
18. Targeting USP9X-AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma.
Zhang FK; Ni QZ; Wang K; Cao HJ; Guan DX; Zhang EB; Ma N; Wang YK; Zheng QW; Xu S; Zhu B; Chen TW; Xia J; Qiu XS; Ding XF; Jiang H; Qiu L; Wang X; Chen W; Cheng SQ; Xie D; Li JJ
Cell Mol Gastroenterol Hepatol; 2022; 14(1):101-127. PubMed ID: 35390516
[TBL] [Abstract][Full Text] [Related]
19. Potential therapeutic targets in ARID1A-mutated cancers.
Bitler BG; Fatkhutdinov N; Zhang R
Expert Opin Ther Targets; 2015; 19(11):1419-22. PubMed ID: 26125128
[TBL] [Abstract][Full Text] [Related]
20. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism.
Morel D; Almouzni G; Soria JC; Postel-Vinay S
Ann Oncol; 2017 Feb; 28(2):254-269. PubMed ID: 28426098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
